Dr. Anna Pavlick on Options for First-Line Therapy in Late-Stage Melanoma
Cancer Network spoke with Anna Pavlick, MD, of NYU's Perlmutter Cancer Center, regarding whether there is one correct answer to front-line therapy for the treatment of advanced melanoma.
Cancer Network spoke with Anna Pavlick, MD, medical oncologist at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, regarding whether there is one correct answer to front-line therapy for the treatment of late-stage melanoma. Pavlick presented on this topic during an educational session at ASCO 2019.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Recent Videos
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
Related Content
